Thoroughly revised for its Third Edition, this volume is the most comprehensive, multidisciplinary text on genitourinary cancers. This edition has two new editors—Frans M.J. Debruyne and W. Marston Linehan—and more than 50% new contributors. Seventeen new chapters cover familial prostate cancer, biology of bone metastases, molecular pathology and biologic determinants, PSA and related kallikreins, needle biopsy, laparoscopic surgical procedures, 3D conformal radiotherapy, hormones and radiotherapy, integration of chemotherapy and other modalities, quality of life after treatment of localized prostate cancer, management of rising PSA after local therapy, the role of surgery in advanced bladder cancer, post-chemotherapy node dissections and resection of metastatic disease, and stem cell transplantation.

This comprehensive and timely textbook covers all aspects of the evidence-based management of genitourinary cancers and explains the fundamental principles underlying the available diagnostic and treatment approaches, including chemotherapy, radiotherapy, immunotherapy, and surgery. For each type of cancer – prostate, bladder, renal, testicular, and penile, plus rare urologic malignancies – clinical presentation, diagnosis, and treatment strategies are described in detail and information is provided on etiology, epidemiology, risk factors, and pathology, including TNM classification. Careful attention is also devoted to the complications that may be encountered when treating urologic malignancies and to the management of these complications. The text is complemented by the inclusion of numerous high-definition photographs and illustrations. Urologic Oncology will be a valuable reference and source of guidance for all oncologists, urologists and practitioners in related disciplines who treat patients with urologic cancers.

Rare Genitourinary Tumors offers the reader an up-to-date discussion of the less common neoplasms affecting the urinary tract and reproductive organs. Each authoritative chapter provides and in-depth discussion that is frequently not found in other urologic oncology textbooks. A valuable reference for urologists, oncologists, and those in specialty training, this volume provides ready access to information on etiology, incidence, risk factors, diagnosis, prognosis, insights from molecular pathology and, where applicable, data from clinical trials. The practical treatment guidelines included for each tumor type are written by experts and fully referenced.

Urologists and medical oncologists have witnessed a rapid growth in systemic therapeutic options for treating genitourinary malignancies that increasingly integrates radiation therapy to primary cancers, nodal beds, and even metastatic sites. The culmination of these advances has been the creation of multidisciplinary teams that expertly provide comprehensive care to patients with urologic cancers. This book provides the framework to create such a multidisciplinary clinical team focused on the treatment of urologic malignancies with representation from urologists, medical oncologists, and additional specialists who work together to provide optimal team-based care. The book integrates advanced systemic therapeutics including immune-based and targeted therapies. Readers gain a better understanding of the benefit of multidisciplinary co-management through specific examples such as hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, and immunotherapy approaches to advanced bladder and kidney cancer. The book also discusses the integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection, emphasizing the expansion of new therapeutics for urologic malignancies and the changing definitions of disease progression. Urologic Oncology: Multidisciplinary Care for Patients is a comprehensive resource for urologists, medical oncologists, radiation oncologists, genetic counselors, fellows in urologic oncology and medical oncology, residents in urology and radiation oncology, advanced practice providers, practice managers, and pharmaceutical representatives.

This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP. Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects.

Designed For Both Oncologists And Urologists, Dx/Rx: Genitourinary Oncology Is A Current, Concise, Quick Reference Guide To The Diagnosis And Therapy Of Cancers Of The Bladder/Urothelial Tract, Kidneys, And Testis. Tightly Organized Into A Super-Condensed Outline-Bulleted Format, This Handy, Pocket-Sized Manual Details Precise, Up-To-Date Information On The Epidemiology, Classification, Diagnosis, Treatment, And Risk Factors Of Genitourinary Disorders. Throughout The Book, Tables And Figures Summarize Important Clinical Data And Current Professional Society Recommendations, While Salient References Direct Readers To Additional Information.

Urologists and medical oncologists have witnessed a rapid growth in systemic therapeutic options for treating genitourinary malignancies that increasingly integrates radiation therapy to primary cancers, nodal beds, and even metastatic sites. The culmination of these advances has been the creation of multidisciplinary teams that expertly provide comprehensive care to patients with urologic cancers. This book provides the framework to create such a multidisciplinary clinical team focused on the treatment of urologic malignancies with representation from urologists, medical oncologists, and additional specialists who work together to provide optimal team-based care. The book integrates advanced systemic therapeutics including immune-based and targeted therapies. Readers gain a better understanding of the benefit of multidisciplinary co-management through specific examples such as hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, and immunotherapy approaches to advanced bladder and kidney cancer. The book also discusses the integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection, emphasizing the expansion of new therapeutics for urologic malignancies and the changing definitions of disease progression. Urologic Oncology: Multidisciplinary Care for Patients is a comprehensive resource for urologists, medical oncologists, radiation oncologists, genetic counselors, fellows in urologic oncology and medical oncology, residents in urology and radiation oncology, advanced practice providers, practice managers, and pharmaceutical representatives.

Handbook of Prostate Cancer and Other Genitourinary Malignancies provides a patient-centered, practical approach to diagnosis, treatment, and clinical management of cancers found in the genitourinary system. With the recent surge of new available treatments, new AJCC Staging guidelines and changes in approaches to care, remaining current and up-to-date can be extremely challenging for practicing clinicians. This comprehensive, multidisciplinary handbook is designed with the busy oncologist, urologist, general practitioner, and trainee in mind. The handbook discusses the standards and controversies of care for managing each genitourinary malignancy and stage of disease, including expert insight and recommendations for making treatment decisions from oncologists and urologists. Clearly marked key points emphasize the most important concepts in each chapter, while numerous tables and figures summarize and highlight important information for quick reference. Handbook of Prostate Cancer and Other Genitourinary Malignancies is an indispensable guide for all oncologists, urologists, and practitioners who regularly care for prostate cancer patients and patients with kidney cancer, bladder cancer, upper urothelial tract cancer, testicular cancer, or penile cancer. Key Features: Delivers the need-to-know points of prostate cancer screening, including recommendations on how to assess severity, avoid misdiagnosis, and mitigate overtreatment of low-grade prostate cancer Provides clinical pearls and treatment recommendations for patients who don’t ‘fit’ the standard guidelines Covers all FDA-approved therapies for each genitourinary malignancy and indicates therapies that are in clinical trials Prepares physicians for challenging case scenarios and treatment decisions where controversies to clinical management persist Includes recommendations and best practices for follow up and survivorship care Summarizes AJCC staging criteria from the 8th Edition

Designed for both oncologists and urologists, Dx/Rx: Genitourinary Oncology is a current, concise, quick reference guide to the diagnosis and therapy of cancers of the bladder/urothelial tract, kidneys, and testis. Tightly organized into a super-condensed outline-bulleted format, this handy, pocket-sized manual details precise, up-to-date information on the epidemiology, classification, diagnosis, treatment, and risk factors of genitourinary disorders. Throughout the book, tables and figures summarize important clinical data and current professional society recommendations, while salient references direct readers to additional information.

This book addresses the most pressing current questions in the management of urologic malignancies. The rapid advances in imaging and molecular markers are placed into a clinical context, with explanation of their effects on prognosis and treatment planning. Similarly, progress in immunotherapy is carefully examined, focusing in particular on the role of immune checkpoint inhibitors in both early- and late-stage urologic malignancies. Looking beyond the improvements in minimally invasive techniques for urologic cancers, the impacts of care coordination pathways and enhanced recovery after surgery protocols are reviewed. Readers will also find enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited. The penultimate chapter discusses the Cancer Genome Atlas project for bladder cancer, and the book closes by considering contemporary medical and surgical management of testicular cancer.